 OncLive | Novel Treatments for Chronic Lymphocytic Leukemia OncLive In an effort to further improve efficacy and reduce toxicity, lenalidomide was explored in combination with the monoclonal antibody rituximab, reporting an ORR of 66% in relapsed CLL and 75% overall survival (OS) at 36 months. Tumor flare and TLS, ... |
